CANTAS Stock Overview
A biotechnology company, develops antibody-based treatments for life threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cantargia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr4.17 |
| 52 Week High | kr8.57 |
| 52 Week Low | kr3.12 |
| Beta | 1.66 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 10.77% |
| 33 Year Change | -93.92% |
| 5 Year Change | n/a |
| Change since IPO | -72.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| CANTAS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | 1.1% |
| 1Y | 10.8% | -25.4% | 8.1% |
Return vs Industry: CANTAS exceeded the UK Biotechs industry which returned -28.7% over the past year.
Return vs Market: CANTAS exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
| CANTAS volatility | |
|---|---|
| CANTAS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: CANTAS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CANTAS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 23 | Goran Forsberg | cantargia.com |
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04 (Nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer and non-small cell lung cancer, as well as Phase Ib/II for the treatment of triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It is also developing CANxx, an IL1RAP-based antibody platform.
Cantargia AB (publ) Fundamentals Summary
| CANTAS fundamental statistics | |
|---|---|
| Market cap | kr702.79m |
| Earnings (TTM) | -kr299.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs CANTAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CANTAS income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr299.38m |
| Earnings | -kr299.37m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 22, 2024
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CANTAS perform over the long term?
See historical performance and comparison